• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Q/C Technologies Inc.

    3/31/26 4:30:23 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QCLS alert in real time by email
    NT 10-K 1 formnt10-k.htm NT 10-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

     

      For Period Ended: December 31, 2025

     

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

     

      For the Transition Period Ended:  
         

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I – REGISTRANT INFORMATION

     

    Q/C Technologies, Inc.

    Full Name of Registrant

     

    TNF Pharmaceuticals, Inc.

    Former Name if Applicable

     

    1185 Avenue of the Americas, Suite 249

    Address of Principal Executive Office (Street and Number)

     

    New York, NY 10036

    City, State and Zip Code

     

     

     

     

     

     

    PART II – RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III – NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Q/C Technologies, Inc. (the “Company”) is unable to file, without unreasonable effort and expense, its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Form 10-K”), because the Company requires additional time to complete and finalize its financial statements required to be included in the Form 10-K. The Company currently anticipates that the Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date.

     

    PART IV – OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Joshua Silverman   856   848-8698
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐
       
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
      Yes ☐ No ☒
       

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    2

     

     

    Q/C Technologies, Inc.

    (Name of registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 31, 2026   By: /s/ Joshua Silverman
          Name: Joshua Silverman
          Title: Executive Chairman

     

    3

     

    Get the next $QCLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QCLS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QCLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Q/C Technologies Launches Optical Processing Unit (OPU) Initiative to Develop Proprietary Silicon Photonic Computing Architecture for AI Inference

      New initiative aimed at developing optical computing technologies to overcome the performance and energy limitations of traditional electronic architectures New York, NY, March 18, 2026 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C" or "the Company"), today announced the launch of a new initiative to design and prototype a proprietary optical processing unit (OPU) aimed at tackling the growing performance and energy constraints in artificial intelligence inference infrastructure. Optical computing overcomes challenges posed by electronic GPUs. Artificial intelligence is dominated by one operation: the matrix multiplication. Photons can be configured to perform matrix m

    3/18/26 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors

    New York, NY, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C Technologies" or "the Company"), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Chelsea Voss to its Board of Directors. Ms. Voss is a computer scientist and Member of Technical Staff at OpenAI, where she has played a key role in the development, evaluation, and launch of some of the most advanced, widely used artificial intelligence systems. Her expertise spans machine learning infrastructure, model evaluation, hardware reliability, and published research contributions including results across image generation, ML interpretability, and reinforcement le

    1/20/26 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli

    New York, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C" or "the Company"), a pioneer of quantum-class computing at the speed of light, today announced that Martin Shkreli become a Strategic Advisor to the Company, contributing his experience in technology, industry contacts, financial innovation and early-stage growth. Q/C Technologies welcomes Martin as part of its expanding advisory team alongside James Altucher, further strengthening the Company's depth of expertise across computing, AI, and blockchain technologies. "I'm convinced that the next leap in frontier computing is optical, not purely quantum. Q/C's ‘quantum class' technology approach bridges f

    12/9/25 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QCLS
    SEC Filings

    View All

    SEC Form 10-K filed by Q/C Technologies Inc.

    10-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    4/15/26 5:20:18 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form NT 10-K filed by Q/C Technologies Inc.

    NT 10-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    3/31/26 4:30:23 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    3/13/26 4:30:38 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QCLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by White Billy Joe

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    4/15/26 6:29:10 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Friscia Stephen

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    4/15/26 6:29:11 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Voss Chelsea Sierra

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    4/15/26 6:29:11 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QCLS
    Leadership Updates

    Live Leadership Updates

    View All

    Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors

    New York, NY, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C Technologies" or "the Company"), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Chelsea Voss to its Board of Directors. Ms. Voss is a computer scientist and Member of Technical Staff at OpenAI, where she has played a key role in the development, evaluation, and launch of some of the most advanced, widely used artificial intelligence systems. Her expertise spans machine learning infrastructure, model evaluation, hardware reliability, and published research contributions including results across image generation, ML interpretability, and reinforcement le

    1/20/26 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives

    Dr. Frankel brings extensive knowledge and deep expertise that bridges advanced physics and quantum technologies New York, NY, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C" or the "Company"), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Steven Frankel, Ph.D. as Senior Quantum Advisor. Dr. Frankel will help guide the Company's ongoing efforts in quantum-class photonic computing to advance the development and commercialization of Q/C's innovative Laser Processing Unit (LPU). Developed by LightSolver, Q/C's LPU is the world's first light and laser-based computing system designed to solve complex optimization an

    10/16/25 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care